Navigation Links
Faust Pharmaceuticals' Phase IIa Results for Parkinson's Disease,Presented at International Congress of Parkinson's Disease and,Movement Disorders

Faust's lead molecule, FP0011, exhibited a differentiated combination of therapeutic effects and good tolerance in mid- to late-stage patients

STRASBOURG, France, June 6, 2007 - Faust Pharmaceuticals S.A., a clinical stage product company specializing in the discovery and development of drugs for diseases of the nervous system, today announced that the Phase IIa clinical trial results of its small molecule glutamate release inhibitor, FP0011, are being presented at the Movement Disorder Society (MDS)'s 11th International Congress of Parkinson's Disease and Movement Disorders, taking place this week in Istanbul, Turkey. The poster, presented by the study's Principal Investigator, Olivier Rascol, M.D., of University Hospital, Toulouse, has been selected for presentation at the Highlights of Posters session during the conference.

In the trial, FP0011 was well tolerated and improved Parkinsonian symptoms as measured by the Unified Parkinson's Disease Rating Scale (UPDRS), as well as motor fluctuations as measured by patient diaries. The compound had positive effects in three critical areas: "core" Parkinsonian motor symptoms (such as tremor, rigidity and akinesia), axial symptoms not sensitive to L-dopa and other commonly-prescribed dopaminergic drugs (such as disturbance of posture, balance and gait), and dyskinesia (i.e. the jerky uncontrolled movements that result as a side effect of long term L-dopa therapy).

The Phase IIa trial was conducted according to an innovative "n of 1" trial design in which a small population (n=8) of mid-to-late stage Parkinsonian patients with L-dopa-induced motor complications were administered FP0011 or placebo over 4 cross-over periods on a randomized, blinded basis.

Professor Rascol, Dr. Joaquim Ferreira (Lisbon), and Dr. Lucette Lacomblez (Paris), were principal investigators in this Phase II trial. The "n of 1" trial design was previously used by Dr. Ferrei ra to confirm that amantadine, originally developed as an antiviral and now commonly used to address side effects of L-dopa therapy, could help Parkinson's patients.

"The differentiated profile observed in this Phase II trial is interesting and intriguing as there are currently no other drugs with this combination of therapeutic effects," said Professor Rascol. "Particularly if the therapeutic effect on non-levodopa sensitive symptoms can be confirmed in the Phase IIb and subsequent trials, the compound would address a very important unmet medical need for all mid-to-late stage patients developing postural disturbances, and could represent a significant advance in approaches to Parkinson's disease."

Also being presented at the conference is a poster on the results of FP0011 in a MPTP macaque monkey model of Parkinson's disease, by Dr. Jonathan Brotchie, CEO of Atuka Ltd. of Toronto, Canada. In this trial, monkeys that have developed dyskinesia from the administration of L-dopa to treat Parkinsonian symptoms from the neurotoxin, MPTP, were administered FP0011. FP0011 reduced the severity of L-dopa-induced dyskinesia while extending the duration of the anti-Parkinsonian action of L-dopa.

"Unlike other drugs on the market that increase the duration of L-dopa action, FP0011 did not exacerbate the problem of dyskinesia," said Dr. Brotchie. "If these effects were seen in patients, then over the course of a day such an action could significantly enhance the quality of life of people with advanced Parkinson's disease."

Commenting on these presentations, Thomas Seoh, CEO of Faust noted that: "These mutually supportive data in the Phase IIa trial and the MPTP monkey trial presented at this conference strongly support the further clinical development of FP0011 as an adjunctive therapy to L-dopa in patients with established motor complications. We look forward to confirming and extending these results in larger trials for Parkinson's patients. Ultima tely, we hope to demonstrate that FP0011 can be a potent, safe glutamate release inhibitor that could have a role in other neurological diseases and conditions where excess glutamate has been implicated, such as Alzheimer's disease, ALS, Huntington's disease, multiple sclerosis and neuropathy."

About Parkinson's disease Parkinson's disease affects both men and women in almost equal numbers with no apparent social, ethnic, economic or geographic links. In the United States, it is estimated that 60,000 new cases are diagnosed each year, joining the 1.5 million Americans who currently have Parkinson's disease. While the condition usually develops after the age of 65, 15% of those diagnosed are under 50. Estimates range up to about 1,200,000 patients in Europe.

About Faust Pharmaceuticals - Faust Pharmaceuticals is a clinical stage products company specializing in the discovery and development of drugs for diseases of the nervous system. The company's lead compound, FP0011, is a small molecule glutamate inhibitor in Phase II for Parkinson's disease and ALS. A second compound, FP0023, is a fetal gene activating utrophin inducer in preparation for Phase I/II for Duchenne Muscular Dystrophy. The company additionally has pre-clinical programs on targets such as mGluR (metabotropic glutamate receptor), as well as a proprietary drug discovery platform targeting GPCRs (G-Protein Coupled Receptors).

For further information, please contact:
Andrew Lloyd & Associates Andrew Lloyd / Neil Hunter Tel: +44 1273 675100> />


Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01


Related medicine technology :

1. Data from Rexahn Pharmaceuticals Phase I Trial of RX-0201 (Archexin) to Be Presented at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago
2. VGX Pharmaceuticals Novel HIV and Pandemic Influenza DNA Vaccine Candidates Trigger Robust Immune Responses and Protection in Pre-Clinical Models
3. Aeolus Pharmaceuticals AEOL 10113 May Play an Important Role Regulating the Oxidative Damage Induced by Ionizing Radiation
4. Aeolus Pharmaceuticals AEOL 10113 Demonstrates Potential as a Protector of Healthy Normal Cells from Cancer Radiation Therapy
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. ACADIA Pharmaceuticals Schizophrenia Programs to Be Presented at the 2007 International Congress on Schizophrenia Research
7. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
8. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
9. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:11/26/2015)... 26, 2015 Research and Markets ( ) ... Pacemaker Market Outlook to 2019 - Rise in Cardiac Disorders ... report to their offering. Boston ... Boston scientific and others. --> ... Biotronik, Boston scientific and others. ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "2016 Future Horizons ... of Abuse Testing Market: Supplier Shares, Country ... report to their offering. --> ... the "2016 Future Horizons and Growth ...
(Date:11/26/2015)... November 26, 2015 ... universitetssjukhus ser potential att använda SyMRI för ... för patienter med multipel skleros (MS) ... med SyntheticMR AB för att kunna använda ... sjukhuset. Med SyMRI kan man generera flera ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... November 27, 2015 , ... ... toilets were," said an inventor from Hillside, N.J. "Many people catch diseases simply ... so that individuals will always be protected from germs." , He developed the ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print component ... Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation of ... distributed nationally, through a vast social media strategy and across a network of ...
(Date:11/27/2015)... ... 2015 , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% ... More than 3.7 billion people under the age of 50 – or 67% of the ... first global estimates of HSV-1 infection . , "The data shocks us highly!" said ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... well-respected Microsoft Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for ... of Microsoft Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ ...
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... failing. Secura Consultants has prided itself for not only fulfilling the needs of ... protection solutions at an affordable price and providing top-tier customer service. However, there's ...
Breaking Medicine News(10 mins):